Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW68KF
|
|||
| Drug Name |
5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pompe disease [ICD-11: 5C51.3; ICD-10: E74.0] | Preclinical | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lysosomal alpha-glucosidase (GAA) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Galactose metabolism | |||
| Starch and sucrose metabolism | ||||
| Metabolic pathways | ||||
| Lysosome | ||||
| Pathwhiz Pathway | Galactose Metabolism | |||
| Pathway Interaction Database | Notch-mediated HES/HEY network | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery of a novel noniminosugar acid alpha glucosidase chaperone series. J Med Chem. 2012 Sep 13;55(17):7546-59. | |||
| REF 2 | 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2. N.A.. N.A. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.